TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds
TTC-352, an investigational oral treatment for patients with metastatic ER-positive breast cancer that no longer responds to hormone therapy, was found to be safe and tolerable at high dose in a Phase 1 clinical study. The treatment also showed a potential for effectiveness, with half of those who finished the trial achieving stable disease for several months. As such, TTC-352 may prove to be "a safe and tolerable alternative to chemotherapy" for patients no longer able to use hormone therapy, its researchers said. Their study, "Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy," was published in the journal Breast Cancer Research and Treatment. Roughly 80% of breast cancers are considered ER-positive, meaning that the cancer cells express the protein estrogen receptor (ER), and respond to the presence of the hormone estrogen in promoting their growth. Hormone therapies like tamoxifen, or fulvestrant (brand name Faslodex, by AstraZeneca), are designed to lower the production of estrogen or to block estrogen from binding to its receptors, limiting tumor growth. Roughly half of breast cancer patients who are treated with hormone therapy, however, become resistant to this type of treatment. When this occurs, chemotherapy is often the only remaining treatment option. Researchers at the University of Illinois Chicago (UIC) developed a potential treatment, called TTC-352, for ER-positive breast cancer patients who are resistant to hormone therapy. “While there are many treatments for breast cancer, about half of women with ER-positive cancers become resistant to hormone therapy, leaving them with few treatments other than chemotherapy, with its well-known toxic side effects,”
Subscribe or to access all post and page content.